Novo Nordisk reached an important R&D milestone on May 14, announcing a deal worth up to $2.2 billion with Septerna to develop drugs to treat obesity and other cardiometabolic diseases.

Read on for a whirlwind, worldwide tour of recent personnel moves. A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the ...

Novo Nordisk has reached the end of its two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for breaches of its code of practice, after showing "significant and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of 3:01:15 pm GMT+2. Market open.